Shenzhen Lifotronic Technology Co., Ltd. (SHA:688389)
China · Delayed Price · Currency is CNY 11.46
+0.16 (1.42%)
Aug 14, 2026, 3:00 PM CST
SHA:688389 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,083 | 1,038 | 1,148 | 1,146 | 983.04 | 778.11 |
Revenue Growth | 2.42% | -9.60% | 0.20% | 16.55% | 26.34% | 40.50% |
Gross Profit Gross Profit Growth | 665.46 | 646.47 | 763.44 | 700.62 | 570.92 | 476.25 |
Operating Income Operating Income Growth | 152.77 | 150.69 | 332.52 | 310.54 | 205.68 | 166.64 |
Net Income Net Income Growth | 163.02 | 184.22 | 345.39 | 328.58 | 251.48 | 190.35 |
Earnings Per Share EPS Growth | 0.38 | 0.43 | -46.91 | 0.77 | 0.60 | 0.45 |
EPS Growth | -43.91% | - | - | 28.33% | 33.33% | 32.35% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Treatment and Rehabilitation - Medical Products Treatment and Rehabilitation - Medical Products Growth | 181.72 |
Treatment and Rehabilitation - Home Products Treatment and Rehabilitation - Home Products Growth | 56.2 |
in Vitro Diagnostics - Inspection Equipment in Vitro Diagnostics - Inspection Equipment Growth | 249.37 |
in Vitro Diagnostics - Test Reagents in Vitro Diagnostics - Test Reagents Growth | 528.4 |
Unallocated Others Unallocated Others Growth | 22.14 |
Total Total Growth | 1,038 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,265 | 1,574 | 1,797 | 1,310 | 931.64 | 808.71 |
Total Debt Total Debt Growth | 149.84 | 398.03 | 600 | 243.48 | 132.61 | 4.13 |
Net Cash (Debt) Net Cash Growth | 1,115 | 1,176 | 1,197 | 1,066 | 799.03 | 804.58 |
Net Cash Growth | 0.98% | -1.78% | 12.26% | 33.43% | -0.69% | -4.52% |
Net Cash Per Share Net Cash Per Share Growth | 2.61 | 2.74 | 2.79 | 2.50 | 1.91 | 1.90 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 306.03 | 280.97 | 296.47 | 303.82 | 271.71 | 182.07 |
Capital Expenditures CapEx Growth | -86.9 | -83.44 | -62.02 | -48.62 | -183.62 | -121.57 |
Free Cash Flow Free Cash Flow Growth | 219.13 | 197.53 | 234.45 | 255.2 | 88.09 | 60.49 |
Free Cash Flow Growth | 9.71% | -15.75% | -8.13% | 189.71% | 45.62% | -26.53% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 61.46% | 62.29% | 66.50% | 61.15% | 58.08% | 61.21% |
Operating Margin | 14.11% | 14.52% | 28.97% | 27.10% | 20.92% | 21.42% |
Pretax Margin | 14.88% | 17.37% | 33.05% | 30.07% | 26.09% | 26.08% |
Profit Margin | 15.05% | 17.75% | 30.09% | 28.68% | 25.58% | 24.46% |
FCF Margin | 20.24% | 19.03% | 20.42% | 22.27% | 8.96% | 7.77% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.282 | 0.282 | 0.282 | 0.281 | 0.237 | 0.178 |
Dividend Per Share Growth | 0% | 0% | 0.36% | 18.57% | 33.15% | 0% |
Dividend Yield | 2.50% | 2.23% | 1.98% | 1.32% | 1.43% | 0.84% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.00 | 30.19 | 18.47 | 29.21 | 29.93 | 51.02 |
Forward PE | 20.65 | 12.73 | 13.51 | 22.94 | 23.77 | 36.08 |
P/FCF Ratio | 22.41 | 28.16 | 27.21 | 37.61 | 85.46 | 160.53 |
PS Ratio | 4.53 | 5.36 | 5.56 | 8.38 | 7.66 | 12.48 |